Marksans Pharma Limited (524404) Fair Value & Analysis
Healthcare · IN · Market cap ₹20.7B
Fair value as of: Aug 18, 2026
From 26 valuation models · updated today
Share price +24.2% over the past month.
A solid business, but screening 54% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹241.62). The favourable scenario is already priced in.
- The model range is unusually wide (₹74.25 to ₹241.62). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range ₹38.92 – ₹352.01 · fair‑value band ₹74.25 – ₹241.62 · the ₹331.65 price screens above the ₹151.74 fair value. Dashed = 300-day average. As of Aug 18, 2026.
Analysis
Marksans Pharma Limited (524404) currently trades at ₹331.65, while our model-based Fair Value estimate is ₹151.74, implying the stock looks roughly 54.3% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Marksans Pharma Limited generated revenue of ₹13.2B at a net margin of 13.1%. Revenue grew 39.0% year over year. It earns a return on equity of 25.5%. The stock trades on a trailing P/E of 12.1 (as of Aug 18, 2026). Fundamentals as of Aug 18, 2026
Our scenario range runs from ₹74.25 (bear case) to ₹241.62 (bull case); at ₹331.65, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 113% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside, at -54%, 524404 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹226.89) versus Dividend Discount (₹10.69). Highest evidence: Growth DCF (80).
Notify me when 524404 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 69
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally.
Full company description
Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, antacid, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, gynecology, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services; and develops and out-licenses patented products. The company was incorporated in 1992 and is headquartered in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Marksans Pharma Limited reported revenue of ₹26.2B in FY2025 versus ₹13.8B in FY2021, a compound +17.5%/yr. Reported net income was ₹3.8B in FY2025, compounding +12.7%/yr from FY2021.
524404 screens 54% overvalued. Compare with AstraZeneca Pharma India Limited →
Peer Group
Health Care · 2250 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| AstraZeneca Pharma India Limited 506820 | ₹7,754 | ₹810.13 | -90% |
| Granules India Limited 532482 | ₹861.80 | ₹420.24 | -51% |
| FDC Limited 531599 | ₹354.40 | ₹255.06 | -28% |
| Bliss GVS Pharma Limited 506197 | ₹524.05 | ₹104.64 | -80% |
| Lincoln Pharmaceuticals Limited 531633 | ₹612.85 | ₹600.51 | -2% |
| Albert David Limited 524075 | ₹808.85 | ₹500.79 | -38% |
| Syncom Formulations (India) Limited 524470 | ₹15.88 | ₹10.20 | -36% |
| Wanbury Limited 524212 | ₹250.55 | ₹226.69 | -10% |
| Makers Laboratories Limited 506919 | ₹153.20 | ₹105.20 | -31% |
| Syschem (India) Limited 531173 | ₹30.91 | ₹7.53 | -76% |
Compare Marksans Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Marksans Pharma Limited (524404) overvalued or undervalued?
What is the fair value of 524404?
What is the quality score of 524404?
What is the revenue of Marksans Pharma Limited (524404)?
What is the net profit margin of 524404?
Does Marksans Pharma Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Marksans Pharma Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.